Tryptamine Therapeutics (ASX:TYP) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tryptamine Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tryptamine Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Tryptamine Therapeutics's Cash-to-Debt or its related term are showing as below:

ASX:TYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.07 Med: 9.95 Max: No Debt
Current: No Debt

During the past 6 years, Tryptamine Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.07. And the median was 9.95.

ASX:TYP's Cash-to-Debt is ranked better than
99.87% of 1486 companies
in the Biotechnology industry
Industry Median: 7.045 vs ASX:TYP: No Debt

Tryptamine Therapeutics Cash-to-Debt Historical Data

The historical data trend for Tryptamine Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tryptamine Therapeutics Cash-to-Debt Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.91

9.38

1.30

1.07

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Cash-to-Debt	Get a 7-Day Free Trial							1.30	1.42	1.07	No Debt	No Debt

Competitive Comparison of Tryptamine Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Tryptamine Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Cash-to-Debt falls into.

Tryptamine Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tryptamine Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.643	/	(1.533	+	0)
	=	1.07

Tryptamine Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Tryptamine Therapeutics had no debt ⁽¹⁾.

Tryptamine Therapeutics (ASX:TYP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tryptamine Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

TYPTF:USA

Address

C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.tryptherapeutics.com

Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines

Tryptamine Therapeutics (ASX:TYP) Cash-to-Debt : No Debt (1) (As of Dec. 2024)